TG reports response rate of 52% for lymphoma candidate

TG has reported detailed interim data from the pivotal Phase IIb UNITY-NHL trial supporting the company's decision to seek accelerated approval from FDA by year end for umbralisib (TGR-1202) to treat marginal zone lymphoma.

At the American Association for Cancer Research (AACR) meeting in Atlanta, TG Therapeutics Inc. (NASDAQ:TGTX) said once-daily oral umbralisib led to an overall response rate (ORR) of 52%, including eight complete responses and 14 partial responses, in a cohort of 42 evaluable patients with relapsed or refractory marginal zone lymphoma. Median duration of response and median progression-free survival (PFS) have not yet been reached at a median follow-up of 12.5 months. The estimated 12-month PFS rate was 66%...